Editor: What To Know
- Charlie’s extensive background in finance, business development, and commercialization and Mitch’s expertise as an engineer with an extensive background in R&D and general management offer valuable additions to our current Board without significant overlap of experience,”.
- Nearly 100 subjects have been treated in four IRB-approved clinical trials, and the Company is currently planning a pivotal clinical study that is planned to begin in the third quarter of 2021.
- Charlie Huiner is an experienced executive in the aesthetic medical device sector, having worked as a senior executive at Inamed, Isologen, and Sientra among others.
October 20, 2020
Charlie Huiner and Mitch Levinson have been added to Recros Medica Board of Directors. Recros Medica is an aesthetic company focused on developing medical devices to reduce skin laxity and improve focal contouring via its Nuvellus® Focal Contouring system. The Nuvellus® platform, based on the company’s proprietary rotational fractional resection technology, may offer a novel procedure that produces results from a single treatment. Nearly 100 subjects have been treated in four IRB-approved clinical trials, and the Company is currently planning a pivotal clinical study that is planned to begin in the third quarter of 2021. The company is also developing Nuvellus® to facilitate autologous dermal transfer, as a natural alternative to commercial dermal fillers.
Charlie Huiner is an experienced executive in the aesthetic medical device sector, having worked as a senior executive at Inamed, Isologen, and Sientra among others. Mitch Levinson was a Co-Founder and the first CEO of Zeltiq, a successful aesthetic device company that was acquired in 2017 for $2.5 billion. The bios of Charlie and Mitch, as well as the other Board Directors.
“We are thrilled to announce the addition of Charlie and Mitch to our Board of Directors. Charlie’s extensive background in finance, business development, and commercialization and Mitch’s expertise as an engineer with an extensive background in R&D and general management offer valuable additions to our current Board without significant overlap of experience,” stated Tom Albright, president, and CEO of Recros Medica. Tom added, “We believe Charlie and Mitch will provide distinct insights to enhance our corporate strategy going forward.”
